CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives
Summary Management of B‐cell acute lymphoblastic leukaemia (B‐ALL) in patients with Down syndrome (DS‐ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS‐ALL, optimal management is uncertain. Chimeric antigen receptor T‐cell (CAR‐T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non‐DS patients. We distributed an international survey to paediatric oncologists treating DS‐ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR‐T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra‐medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR‐T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%–15% for early relapse; 3%–5% for late relapse. The main perceived benefit of CAR‐T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high‐risk relapse of DS‐ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR‐T is warranted for first relapse in DS‐ALL.
Authors
- Rishi Sury Kotecha (ORCID: https://orcid.org/0000-0003-1836-4075)
- Karen R. Rabin (ORCID: https://orcid.org/0000-0002-4081-8195)
- Anupam R. Verma (ORCID: https://orcid.org/0000-0001-6555-7924)
- Susana Rives (ORCID: https://orcid.org/0000-0002-5658-1831)
- Nirali N. Shah (ORCID: https://orcid.org/0000-0002-8474-9080)
- Deepa Bhojwani (ORCID: https://orcid.org/0000-0002-7559-7927)
- Johann K. Hitzler (ORCID: https://orcid.org/0000-0003-1158-186X)
- Jeremy D. Rubinstein (ORCID: https://orcid.org/0000-0002-1934-2954)
- Joerg Krueger (ORCID: https://orcid.org/0000-0003-1225-1977)
- Sara Ghorashian (ORCID: https://orcid.org/0000-0002-1555-2946)
- Colleen Annesley (ORCID: https://orcid.org/0000-0002-3473-0947)
- Sara Zarnegar (ORCID: https://orcid.org/0000-0002-5413-371X)
Institutions
- Northwestern University (US)
- University of Southern California (US)
- Cincinnati Children's Hospital Medical Center (US)
- Lurie Children's Hospital (US)
- Seattle Children's Hospital (US)
- National Institutes of Health (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Children's Hospital of Los Angeles (US)
- The Kids Research Institute Australia (AU)
- The University of Western Australia (AU)
- University of California, San Francisco (US)
- University of Toronto (CA)
- University of Washington (US)
- Curtin University (AU)
- Great Ormond Street Hospital (GB)
- Princess Margaret Hospital for Children (AU)
- Hospital for Sick Children (CA)
- University of California San Francisco Medical Center (US)
- Parc Sanitari Sant Joan de Déu (ES)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Rainbow Babies & Children's Hospital (US)
- Perth Children's Hospital (AU)
- Case Comprehensive Cancer Center (US)
- Case Western Reserve University (US)
- University of Cincinnati (US)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1111/bjh.70945
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00